Keywords: Evotec, Cell Culture Service, M&A, Cell-based reagents, AstraZeneca, MedImmune, Research milestone, Diabetes targets

Evotec acquires Cell Culture Service GmbH; expands deal with AstraZeneca

Article | 07 January 2013

Print This

German biotech firm Evotec (EVT: TecDAX) has acquired all the shares in Cell Culture Service GmbH (CCS), a Hamburg-based company ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in